DK3371152T3 - Sammensætninger omfattende en hæmmer af lysinspecifik demethylase-1 med en pyrimidinring og anvendelse deraf i behandling af cancer - Google Patents
Sammensætninger omfattende en hæmmer af lysinspecifik demethylase-1 med en pyrimidinring og anvendelse deraf i behandling af cancer Download PDFInfo
- Publication number
- DK3371152T3 DK3371152T3 DK16863111.7T DK16863111T DK3371152T3 DK 3371152 T3 DK3371152 T3 DK 3371152T3 DK 16863111 T DK16863111 T DK 16863111T DK 3371152 T3 DK3371152 T3 DK 3371152T3
- Authority
- DK
- Denmark
- Prior art keywords
- inhibitory
- light
- cancer treatment
- compositions including
- pyrimidine ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562251507P | 2015-11-05 | 2015-11-05 | |
| PCT/US2016/060694 WO2017079670A1 (en) | 2015-11-05 | 2016-11-04 | Compositions comprising an inhibitor of lysine specific demethylase-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3371152T3 true DK3371152T3 (da) | 2021-02-15 |
Family
ID=58662888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16863111.7T DK3371152T3 (da) | 2015-11-05 | 2016-11-04 | Sammensætninger omfattende en hæmmer af lysinspecifik demethylase-1 med en pyrimidinring og anvendelse deraf i behandling af cancer |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9828358B2 (ja) |
| EP (1) | EP3371152B1 (ja) |
| JP (1) | JP6995043B2 (ja) |
| CN (1) | CN108473442B (ja) |
| AR (1) | AR106612A1 (ja) |
| AU (1) | AU2016349707B2 (ja) |
| CA (1) | CA3004300C (ja) |
| CY (1) | CY1124078T1 (ja) |
| DK (1) | DK3371152T3 (ja) |
| ES (1) | ES2846951T3 (ja) |
| HR (1) | HRP20210144T8 (ja) |
| HU (1) | HUE053449T2 (ja) |
| LT (1) | LT3371152T (ja) |
| MX (2) | MX2018005620A (ja) |
| PL (1) | PL3371152T3 (ja) |
| PT (1) | PT3371152T (ja) |
| RS (1) | RS61404B1 (ja) |
| SI (1) | SI3371152T1 (ja) |
| TW (1) | TW201720808A (ja) |
| WO (1) | WO2017079670A1 (ja) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62874B1 (sr) * | 2014-05-01 | 2022-02-28 | Celgene Quanticel Research Inc | Inhibitori lizin specifične demetilaze-1 |
| WO2017079670A1 (en) * | 2015-11-05 | 2017-05-11 | Celgene Quanticel Research, Inc. | Compositions comprising an inhibitor of lysine specific demethylase-1 |
| WO2018083189A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| EP3551178A1 (en) | 2016-12-09 | 2019-10-16 | Constellation Pharmaceuticals, Inc. | Markers for personalized cancer treatment with lsd1 inhibitors |
| MX2020001323A (es) | 2017-08-03 | 2020-03-20 | Oryzon Genomics Sa | Metodos para tratar alteraciones del comportamiento. |
| JP2022525679A (ja) | 2019-03-20 | 2022-05-18 | オリソン ヘノミクス，ソシエダ アノニマ | 境界性パーソナリティ障害の処置方法 |
| US20220151999A1 (en) | 2019-03-20 | 2022-05-19 | Oryzon Genomics, S.A. | Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat |
| AU2020290508A1 (en) * | 2019-06-13 | 2022-01-27 | Celgene Corporation | Methods of treating cancer by targeting cold tumors |
| WO2020257671A1 (en) * | 2019-06-20 | 2020-12-24 | Celgene Corporation | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
| WO2021004610A1 (en) | 2019-07-05 | 2021-01-14 | Oryzon Genomics, S.A. | Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors |
| EP4161507A1 (en) * | 2020-06-05 | 2023-04-12 | Celgene Quanticel Research, Inc. | Methods of treating prostate cancer |
| ES2919083R1 (es) * | 2020-06-29 | 2022-07-26 | Celgene Quanticel Res Inc | Métodos de tratamiento de cáncer de próstata |
| MX2023011779A (es) | 2021-04-08 | 2023-11-22 | Oryzon Genomics Sa | Combinaciones de inhibidores de lsd1 para el tratamiento de canceres mieloides. |
| WO2023217758A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| WO2023217784A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
| WO2024110649A1 (en) | 2022-11-24 | 2024-05-30 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| CA2513414A1 (en) * | 2002-04-10 | 2003-10-16 | Orchid Chemicals & Pharmaceuticals Limited | Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases |
| US20030232813A1 (en) * | 2002-04-10 | 2003-12-18 | Orchid Chemicals & Pharmaceuticals Limited | Novel amino substituted pyrimidinone derivatives |
| JP2008515902A (ja) * | 2004-10-06 | 2008-05-15 | エヌピーエス ファーマシューティカルズ インコーポレイテッド | カルシウム拮抗化合物としての相補ピリミジノン化合物 |
| TW201016676A (en) * | 2008-10-03 | 2010-05-01 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
| ES2699351T3 (es) * | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
| RS62874B1 (sr) * | 2014-05-01 | 2022-02-28 | Celgene Quanticel Research Inc | Inhibitori lizin specifične demetilaze-1 |
| WO2017079670A1 (en) * | 2015-11-05 | 2017-05-11 | Celgene Quanticel Research, Inc. | Compositions comprising an inhibitor of lysine specific demethylase-1 |
-
2016
- 2016-11-04 WO PCT/US2016/060694 patent/WO2017079670A1/en active Application Filing
- 2016-11-04 PL PL16863111T patent/PL3371152T3/pl unknown
- 2016-11-04 CA CA3004300A patent/CA3004300C/en active Active
- 2016-11-04 MX MX2018005620A patent/MX2018005620A/es active IP Right Grant
- 2016-11-04 MX MX2020004894A patent/MX2020004894A/es unknown
- 2016-11-04 RS RS20210094A patent/RS61404B1/sr unknown
- 2016-11-04 LT LTEP16863111.7T patent/LT3371152T/lt unknown
- 2016-11-04 HU HUE16863111A patent/HUE053449T2/hu unknown
- 2016-11-04 JP JP2018522953A patent/JP6995043B2/ja active Active
- 2016-11-04 EP EP16863111.7A patent/EP3371152B1/en active Active
- 2016-11-04 PT PT168631117T patent/PT3371152T/pt unknown
- 2016-11-04 SI SI201631055T patent/SI3371152T1/sl unknown
- 2016-11-04 ES ES16863111T patent/ES2846951T3/es active Active
- 2016-11-04 DK DK16863111.7T patent/DK3371152T3/da active
- 2016-11-04 US US15/344,426 patent/US9828358B2/en active Active
- 2016-11-04 CN CN201680076854.5A patent/CN108473442B/zh active Active
- 2016-11-04 AU AU2016349707A patent/AU2016349707B2/en active Active
- 2016-11-07 TW TW105136105A patent/TW201720808A/zh unknown
- 2016-11-07 AR ARP160103391A patent/AR106612A1/es unknown
-
2017
- 2017-10-25 US US15/793,512 patent/US10047069B2/en active Active
-
2018
- 2018-07-10 US US16/032,002 patent/US10316016B2/en active Active
-
2019
- 2019-06-10 US US16/436,541 patent/US10703739B2/en active Active
-
2021
- 2021-01-27 HR HRP20210144TT patent/HRP20210144T8/hr unknown
- 2021-01-28 CY CY20211100072T patent/CY1124078T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3371152T3 (da) | Sammensætninger omfattende en hæmmer af lysinspecifik demethylase-1 med en pyrimidinring og anvendelse deraf i behandling af cancer | |
| DK3554631T3 (da) | Behandling af patienter med ttfields med elektrodepositionerne optimeret under anvendelse af deformerbare skabeloner | |
| DK3678668T3 (da) | ENPP1-inhibitorer og deres anvendelse til behandling af kræft | |
| DK3558997T3 (da) | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer | |
| DK3325488T3 (da) | Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer | |
| DK3842429T3 (da) | Heterocykliske inhibitorer af ERK1 og ERK2 og anvendelse deraf i behandling af cancer | |
| DK3259253T3 (da) | Sulfonylureaer og relaterede forbindelser og brug af samme | |
| DK3134125T3 (da) | Antistof-lægemiddel-konjugat og anvendelse deraf til behandling af cancer | |
| DK3612517T3 (da) | Bicykliske forbindelser og deres anvendelse ved behandling af cancer | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3076972T3 (da) | Cancerbehandling med kombination af plinabulin og taxan | |
| DK3160470T3 (da) | Analoger af pridopidin, fremstilling og anvendelse heraf | |
| DK3182962T3 (da) | Compositions and uses of amidine derivatives | |
| DK3303339T3 (da) | Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme | |
| DK3487505T3 (da) | Indgivelse og dosering af diaminophenothiaziner | |
| DK3204497T3 (da) | Terapeutisk hæmning af lactatdehydrogenase og midler dertil | |
| DK2964255T3 (da) | Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI) | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| DK3458052T3 (da) | Kombinationsbehandling af cancer | |
| DK3375869T3 (da) | Mutanter af uspecifik peroxygenase med høj monooxygenaseaktivitet og anvendelser deraf | |
| DK3331879T3 (da) | Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne | |
| DK3273995T3 (da) | Kombineret anvendelse af alginatoligomerer og cftr-modulatoren lumacaftor i behandlingen af tilstande associeret med cftr-dysfunktion | |
| DK3113782T3 (da) | Lægemiddelleveringssystemer og fremgangsmåder til behandling af blærekræft med gemcitabin | |
| DK3319609T3 (da) | Sammensætninger og fremgangsmåder til anvendelse af antibakterielle lægemiddelkombinationer | |
| DK3297653T3 (da) | Behandling af postbariatrisk hypoglykæmi med glp-1-antagonister |